Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Mallinckrodt
Johnson and Johnson
Colorcon
Merck

Last Updated: May 19, 2022

ABELCET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Abelcet patents expire, and what generic alternatives are available?

Abelcet is a drug marketed by Leadiant Biosci Inc and is included in one NDA.

The generic ingredient in ABELCET is amphotericin b. There are fifteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Abelcet

A generic version of ABELCET was approved as amphotericin b by XGEN PHARMS on April 29th, 1992.

  Try it Free

US Patents and Regulatory Information for ABELCET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ABELCET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 See Plans and Pricing See Plans and Pricing
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ABELCET

See the table below for patents covering ABELCET around the world.

Country Patent Number Title Estimated Expiration
Portugal 86913 PROCESSO DE PREPARACAO DE SISTEMAS DROGA-LIPIDO DE BAIXA TOXICIDADE See Plans and Pricing
Japan H02502460 See Plans and Pricing
Spain 2070131 See Plans and Pricing
Australia 1799088 See Plans and Pricing
Israel 85607 HIGH DRUG:LIPID COMPLEXES AND METHODS FOR THEIR PREPARATION See Plans and Pricing
European Patent Office 0393145 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Express Scripts
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.